Observational Study
. 2020 Nov-Dec:67:100-106. doi: 10.1016/j.genhosppsych.2020.09.004. Epub 2020 Oct 12. Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in MassachusettsAffiliations
AffiliationsItem in Clipboard
Observational Study
Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in MassachusettsJie Yang et al. Gen Hosp Psychiatry. 2020 Nov-Dec.
. 2020 Nov-Dec:67:100-106. doi: 10.1016/j.genhosppsych.2020.09.004. Epub 2020 Oct 12. AffiliationsItem in Clipboard
AbstractObjective: To examine changes in outpatient visits for mental health and/or substance use disorders (MH/SUD) in an integrated healthcare organization during the initial Massachusetts COVID-19 surge and partial state reopening.
Methods: Observational study of outpatient MH/SUD visits January 1st-June 30th, 2018-2020 by: 1) visit diagnosis group, 2) provider type, 3) patient race/ethnicity, 4) insurance, and 5) visit method (telemedicine vs. in-person).
Results: Each year, January-June 52,907-73,184 patients were seen for a MH/SUD visit. While non-MH/SUD visits declined during the surge relative to 2020 pre-pandemic (-38.2%), MH/SUD visits increased (9.1%)-concentrated in primary care (35.3%) and non-Hispanic Whites (10.5%). During the surge, MH visit volume increased 11.7% while SUD decreased 12.7%. During partial reopening, while MH visits returned to 2020 pre-pandemic levels, SUD visits declined 31.1%; MH/SUD visits decreased by Hispanics (-33.0%) and non-Hispanic Blacks (-24.6%), and among Medicaid (-19.4%) and Medicare enrollees (-20.9%). Telemedicine accounted for ~5% of MH/SUD visits pre-pandemic and 83.3%-83.5% since the surge.
Conclusions: MH/SUD visit volume increased during the COVID surge and was supported by rapidly-scaled telemedicine. Despite this, widening diagnostic and racial/ethnic disparities in MH/SUD visit volume during the surge and reopening suggest additional barriers for these vulnerable populations, and warrant continued monitoring and research.
Keywords: COVID-19; Disparities; Health care systems; Mental health; Substance use disorders.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statementDrs. Yang, Zhou, and Busch have not conflict of interest disclosures; Dr. Landrum discloses husband's income from the on-going opioid litigation representing plaintiffs seeking damages.
FiguresFig. 1
Weekly number of mental health…
Fig. 1
Weekly number of mental health and/or substance use disorder (MH/SUD) outpatient visits in…
Fig. 1Weekly number of mental health and/or substance use disorder (MH/SUD) outpatient visits in the healthcare system, January–June 2018–2020 (unadjusted).a a X-axes shows the timeline from January 1st to June 30th 2020 and January 1st to July 1st, 2018 and 2019, scaled and measured in every seven days. We used the 2020 calendar date to align the date information across the three years (after 2/28 of 2018 and 2019, there is one day difference between 2020 and previous two years, i.e. 2/29/2020). Y-axes vary in scale. The first vertical line corresponds to the time period (between 3/11 and 3/17) when Massachusetts declared a state of emergency and provider organization began to discontinue most in-person ambulatory care and transition to telemedicine (i.e., video, phone, or other forms of virtual care [asynchronous e-visits or e-consults]); the second vertical line corresponding to the partial reopening week (between 5/13–5/19). Figures (a) and (b) show that while the number of visits for non-MH/SUD conditions decreased after COVID-19 surge and remained low but increased during the partial reopening in 2020, visits for MH/SUD increased during the surge but then declined. Figures (c) and (d) show that visits for MH increased during the surge and then decreased during reopening, but visits for SUD declined during the surge and reopening. Figures (e) and (f) show that the MH/SUD visit increase primarily occurred in primary care versus MH/SUD specialty during the surge, and then returned to pre-COVID volumes in primary care during reopening.
Similar articlesColey RY, Johnson E, Simon GE, Cruz M, Shortreed SM. Coley RY, et al. JAMA Psychiatry. 2021 Jul 1;78(7):726-734. doi: 10.1001/jamapsychiatry.2021.0493. JAMA Psychiatry. 2021. PMID: 33909019 Free PMC article.
Eberly LA, Kallan MJ, Julien HM, Haynes N, Khatana SAM, Nathan AS, Snider C, Chokshi NP, Eneanya ND, Takvorian SU, Anastos-Wallen R, Chaiyachati K, Ambrose M, O'Quinn R, Seigerman M, Goldberg LR, Leri D, Choi K, Gitelman Y, Kolansky DM, Cappola TP, Ferrari VA, Hanson CW, Deleener ME, Adusumalli S. Eberly LA, et al. JAMA Netw Open. 2020 Dec 1;3(12):e2031640. doi: 10.1001/jamanetworkopen.2020.31640. JAMA Netw Open. 2020. PMID: 33372974 Free PMC article.
Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Ettner SL; Cost Subcommittee of the HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study Group. Weaver MR, et al. J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):449-58. doi: 10.1097/QAI.0b013e3181642244. J Acquir Immune Defic Syndr. 2008. PMID: 18197121
Vakkalanka JP, Gadag K, Lavin L, Ternes S, Healy HS, Merchant KAS, Scott W, Wiggins W, Ward MM, Mohr NM. Vakkalanka JP, et al. Telemed J E Health. 2024 May;30(5):1205-1220. doi: 10.1089/tmj.2023.0588. Epub 2024 Jan 15. Telemed J E Health. 2024. PMID: 38227387 Review.
Alegria M, Carson NJ, Goncalves M, Keefe K. Alegria M, et al. J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):22-31. doi: 10.1016/j.jaac.2010.10.005. Epub 2010 Nov 18. J Am Acad Child Adolesc Psychiatry. 2011. PMID: 21156267 Free PMC article. Review.
Busch AB, Mehrotra A, Greenfield SF, Uscher-Pines L, Rose S, Huskamp HA. Busch AB, et al. J Subst Abuse Treat. 2023 Jan;144:108920. doi: 10.1016/j.jsat.2022.108920. Epub 2022 Oct 28. J Subst Abuse Treat. 2023. PMID: 36334384 Free PMC article.
Zhang Y, Lal LS, Lin YY, Swint JM, Zhang Y, Summers RL, Jones BF, Chandra S, Ladner ME. Zhang Y, et al. Int J Environ Res Public Health. 2024 Jun 22;21(7):819. doi: 10.3390/ijerph21070819. Int J Environ Res Public Health. 2024. PMID: 39063396 Free PMC article.
Leslie K, Bartram M, Atanackovic J, Chamberland-Rowe C, Tulk C, Bourgeault IL. Leslie K, et al. Health Res Policy Syst. 2022 May 7;20(1):51. doi: 10.1186/s12961-022-00857-8. Health Res Policy Syst. 2022. PMID: 35525981 Free PMC article.
Banks DE, Paschke ME, Li X, Fentem A, Rich A, Szlyk HS, Cavazos-Rehg P. Banks DE, et al. J Psychoactive Drugs. 2022 Sep-Oct;54(4):300-308. doi: 10.1080/02791072.2022.2079443. Epub 2022 May 26. J Psychoactive Drugs. 2022. PMID: 35616267 Free PMC article.
Radick AC, James J, Leroux BG, Kim TW, Saxon AJ, Samet JH, Tsui JI. Radick AC, et al. J Addict Med. 2023 May-Jun 01;17(3):300-304. doi: 10.1097/ADM.0000000000001103. Epub 2022 Oct 25. J Addict Med. 2023. PMID: 37267172 Free PMC article. Clinical Trial.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3